Generic drugs

/Tag: Generic drugs

The Little-Known Way Pharma Companies Hook People On Their Costly Drugs

Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. The 36-year-old psychologist had run into an increasingly common problem: The copay coupon sent by Amgen couldn’t cover the drug’s more than $4,000 monthly price. “Nothing in the world gives me

2018-12-13T07:48:27+00:00Tags: |

Epicenter of fake pharma

One consequence of African poverty is that quality medication is often unavailable. Health-care systems tend to be weak, and the marketing of pharmaceuticals is not regulated effectively. Many patients depend on sub-standard or even counterfeit drugs. In this setting, a powerful opioid has become easily available – addiction is spreading in West Africa. Tramadol is

2018-12-13T07:41:21+00:00Tags: |

The New Nonprofit Pharmaceutical World: What’s Up with That?

Two new nonprofit pharmaceutical companies, Civica Rx and Harm Reduction Therapeutics, have declared they want to help patients see more money in their pockets by manufacturing low-cost generic drugs. With public trust in for-profit pharmas at an all-time low, especially when it comes to their relationships with a special brand of self-serving philanthropy, they’d better

2018-09-13T07:49:36+00:00Tags: |

8,000 new antibiotic combinations are surprisingly effective

Scientists have traditionally believed that combining more than two drugs to fight harmful bacteria would yield diminishing returns. The prevailing theory is that that the incremental benefits of combining three or more drugs would be too small to matter, or that the interactions among the drugs would cause their benefits to cancel one another out.

2018-09-05T07:15:22+00:00Tags: |

Working group may vet plan to check fake drugs

NEW DELHI: India’s central drug regulator is creating a working group to critically appraise its proposal to set up a “trace and track” mechanism to weed out fake medicines from the market using unique codes. The working group, comprising pharmaceutical association representatives and members of the Central Drugs Standard Control Organisation, is to submit its

2018-08-21T08:28:29+00:00Tags: |

Price competition for generic drugs linked to increase in manufacturing-related recalls

Researchers from three universities have found that extreme price competition in the generic pharmaceutical market -- designed to make medications more affordable -- may be putting more patients at serious health risk, as evidenced by a higher number of product recalls caused by manufacturing-related problems. The same research, published online today in the Journal of

2018-06-09T08:07:00+00:00Tags: |

Do generic drugs compromise on quality?

You've no doubt seen them in the grocery store — typically drab-looking packages on the bottom shelf containing lower-priced generic versions of popular brand-name products. Some shoppers look at them with skepticism: Are they really as good? Or does cheaper just mean lower quality? Many people have the same questions about generic prescription medications, says

2018-05-29T08:03:45+00:00Tags: |

Nonprofit Manufacturer Could Keep Generic Drug Costs Down

HealthDay News — A nonprofit manufacturer could help keep generic drug prices down and maintain their supply, according to a perspective piece published in the issue of the New England Journal of Medicine. Dan Liljenquist, J.D., from Intermountain Healthcare in Salt Lake City, and colleagues discuss generic drug market failure, whereby a generic drug manufacturer

2018-05-24T04:56:59+00:00Tags: |

How to free Indians from the medical poverty trap

India is the largest supplier of generic drugs in the world, and Indian pharmaceutical companies have famously succeeded in pushing down the cost of medication in many countries across the world. Yet, too many Indian citizens do not get access to medicines owing to high costs. The preferred solution of the government right now—price control—is

2018-05-14T07:40:17+00:00Tags: |

‘Coffee filter’ helps make new cancer drug Z-endoxifen 1000 times cheaper

Making drugs cheaper doesn’t always require pricey investments. A joint initiative by researchers from TU Eindhoven, the Dutch company Syncom BV and the Antoni van Leeuwenhoek hospital proves just that. What started out as a Bachelor project at TU/e laid the foundation for a much cheaper production of the promising cancer drug Z-endoxifen. Tamoxifen is

2018-04-07T09:19:19+00:00Tags: |

Probe Into Generic Drug Price Fixing Set To Widen

Forty-five states and the Department of Justice are claiming that generic-drug prices are fixed and the alleged collusion may have cost U.S. business and consumers more than $1 billion. In their complaint, prosecutors say that when pharmacies asked drugmakers for their lowest price, the manufacturers would rig the bidding process. "The companies would work out

2018-03-31T06:40:05+00:00Tags: |

Generic industry boss: SPC manufacturing waiver won’t harm originators’ innovation

The generic industry’s request for an SPC (supplementary protection certificates)  manufacturing waiver, which would allow them to produce in the EU SPC-protected drugs for other markets, does not influence or harm innovators’ rights, Marc–Alexander Mahl told EURACTIV.com in an interview. He said that the originators’ arguments for rejecting such a waiver and protecting their own rights

2018-03-31T06:17:23+00:00Tags: |

The pioneer of India’s biotech industry was denied her first job for being a woman

After failing the exam for medical school, Kiran Mazumdar-Shaw trained as a professional brewmaster. When no company in India’s male-dominated beer industry would hire her, despite her education and certification, she decided to start her own business developing industrial enzymes. Thirty years later, Mazumdar-Shaw is chairman and CEO of Biocon, India’s largest biotech company and

2018-02-15T11:13:50+00:00Tags: |

Health system-led drug company unlikely to make a dent in drug prices, shortages

As four not-for-profit health systems unveiled plans to create their own generic drug company Thursday, experts say they'll face an uphill battle to make a significant dent in one of the fastest-growing industry expenses and persistent problems: rising drug prices and drug shortages. Intermountain Healthcare, Ascension, SSM Health and Trinity Health are working with the

2018-02-14T07:33:13+00:00Tags: |

Kenya becomes first country to debut generic HIV drug

A new generic version of a frontline antiretroviral drug launches in Kenya today, the first time that HIV patients will have access to the more affordable version of the treatment. Dolutegravir, or DTG, will be available to patients through a partnership between the Kenyan Ministry of Health and Geneva-based Unitaid. DTG has been the preferred

2018-02-07T13:26:21+00:00Tags: |

The power of pharma businesses to drive social change

Poverty, unemployment and inequality are perhaps the biggest challenges facing society today. These issues all urgently need solutions, and businesses bear a responsibility in helping to create them. One of the key ways in which businesses can do this is through Corporate Social Responsibility (CSR) programmes. Investing in CSR programmes can bring business as well

2018-01-31T09:40:26+00:00Tags: |

Hospitals Launch Their Own Generic Drug Company

A consortium of four healthcare groups, citing frustration with ongoing shortages and high costs of generic medications, announced on Jan. 18, 2018 the formation of a not-for-profit generic drug company. The healthcare groups, Ascension, Intermountain Healthcare, SSM Health, and Trinity Health—working in consultation with the US Department of Veterans Affairs (VA)—represent more than 450 hospitals

2018-01-31T09:44:06+00:00Tags: |

FDA Commissioner on new steps to facilitate efficient generic drug review

The FDA today announced additional steps to encourage generic competition as part of our continued implementation of the Drug Competition Action Plan. This plan has three main components: reducing gaming by branded companies that can delay generic drug entry; resolving scientific and regulatory obstacles that can make it difficult to win approval of generic versions

2018-01-05T10:09:55+00:00Tags: |